​

Funding Round

Series B - Qlaris Bio

Series B - Qlaris Bio

Investment Firm

Overview

Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.

Announced Date

Apr 30, 2024

Closed on Date

Apr 30, 2024

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Canaan Partners

Canaan Partners

Canaan Partners is a early_stage_venture and late_stage_venture and seed and venture firm.

New Leaf Venture Partners

New Leaf Venture Partners

New Leaf Venture Partners is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

5

Investor Name
Participant InvestorMayo Clinic Ventures
Participant InvestorNew Leaf Venture Partners
Participant InvestorAbrdn
Participant InvestorCorrelation Ventures
Participant InvestorCanaan Partners

Round Details and Background

Qlaris Bio raised $24000000 on 2024-04-30 in Series B

Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 28, 2019
Series A - Qlaris Bio
4-25.0M
Apr 30, 2024
Series B - Qlaris Bio
5-24.0M

Recent Activity

There is no recent news or activity for this profile.